MiniMed 780G System Maintains Excellent Glycemic Control in Children with Type 1 Diabetes
Background
Type 1 Diabetes (T1D) requires constant management to maintain glycemic control, especially in children where routines vary significantly. Advanced insulin delivery systems like the MiniMed 780G system in auto mode aim to simplify this, but real-world effectiveness across different daily routines, particularly school versus out-of-school days, needs further investigation. This study specifically addresses whether glycemic targets are consistently met in Italian children using the MiniMed 780G system during both school and out-of-school routines.
Results
The analysis revealed that there was no meaningful difference in Time in Range (TIR), the percentage of time glucose levels are within a target range, between school days and out-of-school (OOS) days. On average, children achieved a TIR of 73.4% during school days and 72.4% during OOS days, demonstrating consistent glycemic control that met international targets for both types of days. Despite this overall consistency, minor sensor glucose variations were observed during school hours, including a more pronounced glucose peak after breakfast and a clearer dip before lunch on school days. Crucially, the MiniMed 780G system's insulin delivery algorithm effectively managed these fluctuations, preventing significant deviations from target ranges and maintaining comparable control across different routines.
Why It Matters
This real-world data validates the effectiveness of the MiniMed 780G system in maintaining stable glycemic control for children with Type 1 Diabetes (T1D) across varied daily routines. The consistent achievement of international glycemic targets, regardless of school attendance, is crucial for long-term health outcomes. This sustained control can significantly enhance learning and support optimal cognitive and brain development in children with T1D, potentially improving their quality of life. Future research could explore the long-term impact of such consistent control on neurocognitive development and assess the system's performance in even larger, more diverse pediatric populations.